These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22003912)

  • 41. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
    Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
    Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy.
    Orlandi A; Paolino MC; Striano P; Parisi P
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):505-512. PubMed ID: 29804481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance.
    Rosemary J; Adithan C
    Curr Clin Pharmacol; 2007 Jan; 2(1):93-109. PubMed ID: 18690857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients.
    Zhang Y; Wang J; Zhao LM; Peng W; Shen GQ; Xue L; Zheng XX; He XJ; Gong CY; Miao LY
    Eur J Clin Pharmacol; 2011 Sep; 67(9):885-7. PubMed ID: 21424386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe.
    Dhoro M; Ngara B; Kadzirange G; Nhachi C; Masimirembwa C
    Curr HIV Res; 2013 Sep; 11(6):481-90. PubMed ID: 24517233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.
    Hirota T; Eguchi S; Ieiri I
    Drug Metab Pharmacokinet; 2013; 28(1):28-37. PubMed ID: 23165865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic Predisposition to Anticonvulsant Hypersensitivity.
    Pirmohamed M
    Clin Pharmacol Ther; 2019 Nov; 106(5):919-922. PubMed ID: 31517995
    [No Abstract]   [Full Text] [Related]  

  • 48. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
    Sánchez MB; Herranz JL; Leno C; Arteaga R; Oterino A; Valdizán EM; Nicolás JM; Adín J; Armijo JA
    Seizure; 2010 Mar; 19(2):93-101. PubMed ID: 20064729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs.
    Stępień KM; Tomaszewski M; Tomaszewska J; Czuczwar SJ
    Pharmacol Rep; 2012; 64(5):1011-9. PubMed ID: 23238460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Adverse effects of antiepileptic drugs].
    Takahashi Y; Watanabe H; Yoshitomi S; Tsukamoto K; Yamaguchi T
    Nihon Rinsho; 2014 May; 72(5):908-19. PubMed ID: 24912294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HLA-B*1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs.
    Wang J; Zhang J; Wu X; Yu P; Hong Z
    J Int Med Res; 2012; 40(1):377-82. PubMed ID: 22429379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
    Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
    J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.
    Fohner AE; Rettie AE; Thai KK; Ranatunga DK; Lawson BL; Liu VX; Schaefer CA
    Clin Transl Sci; 2020 Sep; 13(5):1004-1009. PubMed ID: 32216088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic risk factors for antiepileptic drug-induced hypersensitivity reactions in Israeli populations.
    Israel S; Maggio N; Ekstein D; Zaid H; Firer M; Bederovsky Y; Noyman I; Gandelman-Marton R; Blatt I; Brautbar C; Marom E; Nahlieli Dil D; Berman E; Sabag D; Ingber A; Eyal S
    Epilepsia; 2016 Oct; 57(10):e205-e209. PubMed ID: 27527795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland.
    Wang Q; Zhou JQ; Zhou LM; Chen ZY; Fang ZY; Chen SD; Yang LB; Cai XD; Dai QL; Hong H; Wang HX
    Seizure; 2011 Jul; 20(6):446-8. PubMed ID: 21397523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of MDR1 (C3435T) Polymorphism on Resistance, Uptake, and Efflux to Antiepileptic Drugs.
    Shen XM; Cheng J
    DNA Cell Biol; 2019 Mar; 38(3):250-255. PubMed ID: 30632789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epilepsy: HLA alleles linked to carbamazepine hypersensitivity.
    Striano P; Zara F
    Nat Rev Neurol; 2011 Jun; 7(7):365-6. PubMed ID: 21647201
    [No Abstract]   [Full Text] [Related]  

  • 59. Comment on 'Morphology: the mother of all biomarkers'.
    Prignano F; Rosi E
    Br J Dermatol; 2024 Aug; 191(3):471. PubMed ID: 38888182
    [No Abstract]   [Full Text] [Related]  

  • 60. Transcriptomic data-mining approach for identifying potential pharmacogenetic candidates in antiepileptic drug response.
    Sharma A
    Indian J Hum Genet; 2011 May; 17 Suppl 1(Suppl 1):S58-9. PubMed ID: 21747590
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.